Distinct clinical patterns in AQP4-IgG- positive NMOSD patients vs. Seronegative: Insights from a single-center study in Argentina.

Background: Distinct clinical course patterns have been identified between AQP4-IgG-positive and AQP4-IgG-negative NMOSD patients.

Objectives: This study aimed to evaluate the differences between AQP4-IgG-seropositive and AQP4-IgG-seronegative NMOSD patients in a single centre in Argentina.

Methods: We performed a retrospective cross-sectional study of 108 NMOSD patients in the city of Buenos Aires, Argentina.

Unveiling mycobacterial infections in Brazilian swine: Insights from epidemiological and diagnostic studies.

Stringent sanitary standards are imperative for swine production, ensuring high biosecurity and safe meat. However, granulomatous lesions, often detected as "lymphadenitis" in slaughterhouses, lack routine laboratory examination, potentially overlooking tuberculosis among other etiologies. This study aimed to: (i) explore epidemiological variables linked to swine carcasses condemned due to "tuberculosis" or "lymphadenitis" in Rio Grande do Sul, southern Brazil in a retrospective survey; and (ii) evaluate the frequency of Mycobacterium tuberculosis in granulomatous lymphadenitis lesions.

Raman-Enabled Predictions of Protein Content and Metabolites in Biopharmaceutical Fermentations.

Raman spectroscopy, a robust and non-invasive analytical method, has demonstrated significant potential for monitoring biopharmaceutical production processes. Its ability to provide detailed information about molecular vibrations makes it ideal for the detection and quantification of therapeutic proteins and critical control parameters in complex biopharmaceutical mixtures. However, its application in fermentations has been hindered by the inherent strong fluorescence background from the cells.

International Society on Thrombosis and Haemostasis Clinical Practice Guideline for Treatment of Congenital Haemophilia-A Critical Appraisal.

Introduction: Evidence-based clinical practice guidelines drive optimal patient care and facilitate access to high-quality treatment. Creating guidelines for rare diseases such as haemophilia, where evidence does not often come from randomized controlled trials but from non-randomized and well-designed observational studies and real-world data, is challenging. The methodology used for assessing available evidence should consider this critical fact.